Eversept Partners LP Grows Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

Eversept Partners LP increased its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 8.2% in the 1st quarter, Holdings Channel reports. The fund owned 138,036 shares of the company’s stock after buying an additional 10,475 shares during the quarter. Eversept Partners LP’s holdings in Structure Therapeutics were worth $6,653,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. CWM LLC boosted its stake in Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares in the last quarter. HighTower Advisors LLC grew its holdings in Structure Therapeutics by 3.6% in the fourth quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock worth $648,000 after purchasing an additional 320 shares during the period. State of Wyoming increased its stake in shares of Structure Therapeutics by 29.7% during the fourth quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after purchasing an additional 403 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Structure Therapeutics by 4.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock valued at $757,000 after purchasing an additional 444 shares during the last quarter. Finally, Assetmark Inc. boosted its position in shares of Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after purchasing an additional 449 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GPCR has been the topic of several recent research reports. Wall Street Zen downgraded Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a research note on Monday, April 27th. They set a “buy” rating and a $101.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright cut their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $48.69 on Tuesday. The stock has a market capitalization of $3.46 billion, a PE ratio of -55.96 and a beta of -1.50. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $15.80 and a 52-week high of $94.90. The company has a 50-day simple moving average of $45.67 and a two-hundred day simple moving average of $55.70.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.